MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Core Insights - MaxCyte, Inc. provided a preliminary update on its financial results for Q4 and the full year 2025, indicating a challenging yet productive year with core revenue in line with guidance [1][3] - The company reported total cash, cash equivalents, and investments of approximately $155.6 million as of December 31, 2025 [2] - Core revenue for Q4 is expected to be between $6.6 million and $6.7 million, while full-year core revenue is projected to be between $29.5 million and $29.6 million [5] - Strategic Platform License (SPL) program-related revenue for Q4 is expected to be between $0.4 million and $0.6 million, with full-year SPL revenue anticipated to be between $3.3 million and $3.5 million [5] Company Strategy and Outlook - The company aims to improve its cost structure and drive efficient growth towards profitability, entering 2026 with reduced annual burn and a leaner organization [3] - MaxCyte is optimistic about the opportunities presented by its SPLs and the expansion of its SeQure services, expecting a return to revenue growth in the second half of 2026 [3] - The company plans to launch new offerings early in 2026, indicating a focus on innovation and market expansion [3] Technology and Services - MaxCyte specializes in cell engineering, providing technologies that facilitate the discovery, development, and commercialization of next-generation cell therapies [4] - The company’s Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services are designed to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte continues to advance cell engineering, contributing to the future of medicine [4]